Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd is experiencing a favorable trajectory in its utilization rates, having increased over 50% since the establishment of its investment strategy, indicating strong demand for its Deep TMS technology. The recent FDA approval for the Neurolief Proliv™Rx device paves the way for enhanced pricing and market opportunities, while strategic investments are anticipated to drive accelerated revenue growth. Furthermore, the company is enjoying increased receptivity to pay-per-use models and potential growth in the neurologist specialist prescriber segment, which positions it favorably in the evolving mental health treatment landscape.

Bears say

BrainsWay Ltd faces several significant risks that contribute to a negative outlook on its stock. First, there is a concern regarding the slower-than-expected adoption of its Deep TMS systems, which could hinder revenue growth. Additionally, challenges related to expanding reimbursement and market access, as well as the inability to progress in other clinical indications, further exacerbate financial uncertainties, alongside the potential for long-term dilution impacting current shareholders.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Feb 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.